[1]
Zerga, M. 2026. New therapeutic options for relapsed/refractory diffuse large b-cell lymphoma. Treatment with tafasitamab + lenalidomide. Journal of Hematology. 29, 3 (Jan. 2026), 61–70. DOI:https://doi.org/10.48057/hematologa.v29i3.687.